QCLS

SEC source: 0001493152-21-025606 · ownership.xml · derivative · entry 1

Uzonwanne Jude · CIK 0001858040 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 150,000

Underlying: Common Stock · 150,000 shares

Expires not disclosed

F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of common stock of MyMD Pharmaceuticals, Inc. (the "Company").

F2 · derivative.exercise_date: The RSUs vest as follows: (i) 33% if the Company's market capitalization equals or exceeds $500,000,000 for at least 10 trading days during any 20 consecutive trading day period ending on or after December 15, 2021 (the "Required Period") and the fair market value (the "FMV") of the common stock equals or exceeds $5.00, subject to standard adjustments (the "Minimum Share Value") during such Required Period, (ii) 33% if the Company's market capitalization equals or exceeds $750,000,000 for the Required Period at the Minimum Share Value, and (iii) the remainder if the Company's market capitalization equals or exceeds $1,000,000,000 for the Required Period at the Minimum Share Value; provided that the RSUs shall vest immediately upon the occurrence of a change in control that values the Company's common stock at least $500,000,000, provided that the Reporting Person is providing services to the Company on the closing date of such change in control.

F2 · derivative.expiration_date: The RSUs vest as follows: (i) 33% if the Company's market capitalization equals or exceeds $500,000,000 for at least 10 trading days during any 20 consecutive trading day period ending on or after December 15, 2021 (the "Required Period") and the fair market value (the "FMV") of the common stock equals or exceeds $5.00, subject to standard adjustments (the "Minimum Share Value") during such Required Period, (ii) 33% if the Company's market capitalization equals or exceeds $750,000,000 for the Required Period at the Minimum Share Value, and (iii) the remainder if the Company's market capitalization equals or exceeds $1,000,000,000 for the Required Period at the Minimum Share Value; provided that the RSUs shall vest immediately upon the occurrence of a change in control that values the Company's common stock at least $500,000,000, provided that the Reporting Person is providing services to the Company on the closing date of such change in control.

SEC source: 0001493152-21-025602 · ownership.xml · derivative · entry 1

Silverman Joshua · CIK 0001524858 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 600,000

Underlying: Common Stock · 600,000 shares

Expires not disclosed

F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of common stock of MyMD Pharmaceuticals, Inc. (the "Company").

F2 · derivative.exercise_date: The RSUs vest as follows: (i) 33% if the Company's market capitalization equals or exceeds $500,000,000 for at least 10 trading days during any 20 consecutive trading day period ending on or after December 15, 2021 (the "Required Period") and the fair market value (the "FMV") of the common stock equals or exceeds $5.00, subject to standard adjustments (the "Minimum Share Value") during such Required Period, (ii) 33% if the Company's market capitalization equals or exceeds $750,000,000 for the Required Period at the Minimum Share Value, and (iii) the remainder if the Company's market capitalization equals or exceeds $1,000,000,000 for the Required Period at the Minimum Share Value; provided that the RSUs shall vest immediately upon the occurrence of a change in control that values the Company's common stock at least $500,000,000, provided that the Reporting Person is providing services to the Company on the closing date of such change in control.

F2 · derivative.expiration_date: The RSUs vest as follows: (i) 33% if the Company's market capitalization equals or exceeds $500,000,000 for at least 10 trading days during any 20 consecutive trading day period ending on or after December 15, 2021 (the "Required Period") and the fair market value (the "FMV") of the common stock equals or exceeds $5.00, subject to standard adjustments (the "Minimum Share Value") during such Required Period, (ii) 33% if the Company's market capitalization equals or exceeds $750,000,000 for the Required Period at the Minimum Share Value, and (iii) the remainder if the Company's market capitalization equals or exceeds $1,000,000,000 for the Required Period at the Minimum Share Value; provided that the RSUs shall vest immediately upon the occurrence of a change in control that values the Company's common stock at least $500,000,000, provided that the Reporting Person is providing services to the Company on the closing date of such change in control.

SEC source: 0001493152-21-025605 · ownership.xml · derivative · entry 1

EAGLE CRAIG · CIK 0001562135 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 150,000

Underlying: Common Stock · 150,000 shares

Expires not disclosed

F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of common stock of MyMD Pharmaceuticals, Inc. (the "Company").

F2 · derivative.exercise_date: The RSUs vest as follows: (i) 33% if the Company's market capitalization equals or exceeds $500,000,000 for at least 10 trading days during any 20 consecutive trading day period ending on or after December 15, 2021 (the "Required Period") and the fair market value (the "FMV") of the common stock equals or exceeds $5.00, subject to standard adjustments (the "Minimum Share Value") during such Required Period, (ii) 33% if the Company's market capitalization equals or exceeds $750,000,000 for the Required Period at the Minimum Share Value, and (iii) the remainder if the Company's market capitalization equals or exceeds $1,000,000,000 for the Required Period at the Minimum Share Value; provided that the RSUs shall vest immediately upon the occurrence of a change in control that values the Company's common stock at least $500,000,000, provided that the Reporting Person is providing services to the Company on the closing date of such change in control.

F2 · derivative.expiration_date: The RSUs vest as follows: (i) 33% if the Company's market capitalization equals or exceeds $500,000,000 for at least 10 trading days during any 20 consecutive trading day period ending on or after December 15, 2021 (the "Required Period") and the fair market value (the "FMV") of the common stock equals or exceeds $5.00, subject to standard adjustments (the "Minimum Share Value") during such Required Period, (ii) 33% if the Company's market capitalization equals or exceeds $750,000,000 for the Required Period at the Minimum Share Value, and (iii) the remainder if the Company's market capitalization equals or exceeds $1,000,000,000 for the Required Period at the Minimum Share Value; provided that the RSUs shall vest immediately upon the occurrence of a change in control that values the Company's common stock at least $500,000,000, provided that the Reporting Person is providing services to the Company on the closing date of such change in control.

SEC source: 0001493152-21-025601 · ownership.xml · derivative · entry 1

Chapman Christopher C JR · CIK 0001340428 · Director · President, Chief Med. Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 600,000

Underlying: Common Stock · 600,000 shares

Expires not disclosed

F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of common stock of MyMD Pharmaceuticals, Inc. (the "Company").

F2 · derivative.exercise_date: The RSUs vest as follows: (i) 33% if the Company's market capitalization equals or exceeds $500,000,000 for at least 10 trading days during any 20 consecutive trading day period ending on or after December 15, 2021 (the "Required Period") and the fair market value (the "FMV") of the common stock equals or exceeds $5.00, subject to standard adjustments (the "Minimum Share Value") during such Required Period, (ii) 33% if the Company's market capitalization equals or exceeds $750,000,000 for the Required Period at the Minimum Share Value, and (iii) the remainder if the Company's market capitalization equals or exceeds $1,000,000,000 for the Required Period at the Minimum Share Value; provided that the RSUs shall vest immediately upon the occurrence of a change in control that values the Company's common stock at least $500,000,000, provided that the Reporting Person is providing services to the Company on the closing date of such change in control.

F2 · derivative.expiration_date: The RSUs vest as follows: (i) 33% if the Company's market capitalization equals or exceeds $500,000,000 for at least 10 trading days during any 20 consecutive trading day period ending on or after December 15, 2021 (the "Required Period") and the fair market value (the "FMV") of the common stock equals or exceeds $5.00, subject to standard adjustments (the "Minimum Share Value") during such Required Period, (ii) 33% if the Company's market capitalization equals or exceeds $750,000,000 for the Required Period at the Minimum Share Value, and (iii) the remainder if the Company's market capitalization equals or exceeds $1,000,000,000 for the Required Period at the Minimum Share Value; provided that the RSUs shall vest immediately upon the occurrence of a change in control that values the Company's common stock at least $500,000,000, provided that the Reporting Person is providing services to the Company on the closing date of such change in control.

SEC source: 0001493152-21-025600 · ownership.xml · derivative · entry 1

Rivard Paul · CIK 0001857479 · EVP of Operations, GC

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 200,000

Underlying: Common Stock · 200,000 shares

Expires not disclosed

F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of common stock of MyMD Pharmaceuticals, Inc. (the "Company").

F2 · derivative.exercise_date: The RSUs vest as follows: (i) 33% if the Company's market capitalization equals or exceeds $500,000,000 for at least 10 trading days during any 20 consecutive trading day period ending on or after December 15, 2021 (the "Required Period") and the fair market value (the "FMV") of the common stock equals or exceeds $5.00, subject to standard adjustments (the "Minimum Share Value") during such Required Period, (ii) 33% if the Company's market capitalization equals or exceeds $750,000,000 for the Required Period at the Minimum Share Value, and (iii) the remainder if the Company's market capitalization equals or exceeds $1,000,000,000 for the Required Period at the Minimum Share Value; provided that the RSUs shall vest immediately upon the occurrence of a change in control that values the Company's common stock at least $500,000,000, provided that the Reporting Person is providing services to the Company on the closing date of such change in control.

F2 · derivative.expiration_date: The RSUs vest as follows: (i) 33% if the Company's market capitalization equals or exceeds $500,000,000 for at least 10 trading days during any 20 consecutive trading day period ending on or after December 15, 2021 (the "Required Period") and the fair market value (the "FMV") of the common stock equals or exceeds $5.00, subject to standard adjustments (the "Minimum Share Value") during such Required Period, (ii) 33% if the Company's market capitalization equals or exceeds $750,000,000 for the Required Period at the Minimum Share Value, and (iii) the remainder if the Company's market capitalization equals or exceeds $1,000,000,000 for the Required Period at the Minimum Share Value; provided that the RSUs shall vest immediately upon the occurrence of a change in control that values the Company's common stock at least $500,000,000, provided that the Reporting Person is providing services to the Company on the closing date of such change in control.

SEC source: 0001493152-21-009291 · ownership.xml · derivative · entry 3

White Billy Joe · CIK 0001546805 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 109,500 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of common stock of MyMD Pharmaceuticals, Inc. (the "Company").

F3 · derivative.exercise_date: On September 11, 2020, the reporting person was granted 109,500 RSUs of the Company, which vested on April 16, 2021, upon the occurrence of a change in control.

F3 · derivative.expiration_date: On September 11, 2020, the reporting person was granted 109,500 RSUs of the Company, which vested on April 16, 2021, upon the occurrence of a change in control.

SEC source: 0001493152-21-009291 · ownership.xml · nonDerivative · entry 2

White Billy Joe · CIK 0001546805 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 71,175

F2 · shares: Represents 38,325 shares of RSUs withheld to pay the reporting person's tax withholding obligations incurred in connection with the vesting of 109,500 shares of RSUs on April 16, 2021.

SEC source: 0001493152-21-009291 · ownership.xml · nonDerivative · entry 1

White Billy Joe · CIK 0001546805 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 112,101

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · shares: Each restricted stock unit ("RSU") represents a contingent right to receive one share of common stock of MyMD Pharmaceuticals, Inc. (the "Company").

F1 · price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of common stock of MyMD Pharmaceuticals, Inc. (the "Company").

SEC source: 0001493152-21-009297 · ownership.xml · derivative · entry 3

SCHROEDER ROBERT C · CIK 0001268331 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 43,930 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of common stock of MyMD Pharmaceuticals, Inc. (the "Company").

F3 · derivative.exercise_date: On September 11, 2020, the reporting person was granted 43,930 RSUs of the Company, which vested on April 16, 2021, upon the occurrence of a change in control.

F3 · derivative.expiration_date: On September 11, 2020, the reporting person was granted 43,930 RSUs of the Company, which vested on April 16, 2021, upon the occurrence of a change in control.

SEC source: 0001493152-21-009297 · ownership.xml · nonDerivative · entry 2

SCHROEDER ROBERT C · CIK 0001268331 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 29,236

F2 · shares: Represent 14,694 shares of RSUs withheld to pay the reporting person's tax withholding obligations incurred in connection with the vesting of 43,930 shares of RSUs on April 16, 2021.

SEC source: 0001493152-21-009297 · ownership.xml · nonDerivative · entry 1

SCHROEDER ROBERT C · CIK 0001268331 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 43,930

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · shares: Each restricted stock unit ("RSU") represents a contingent right to receive one share of common stock of MyMD Pharmaceuticals, Inc. (the "Company").

F1 · price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of common stock of MyMD Pharmaceuticals, Inc. (the "Company").

SEC source: 0001493152-21-009302 · ownership.xml · derivative · entry 2

Rivard Paul · CIK 0001857479 · EVP of Operations, GC

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 77,180

Underlying: Common Stock · 77,180 shares

Expires 2023-04-16

F3 · price: Received in exchange for a stock option to acquire 200,000 shares of common stock of the Former Entity at $1.00 per share in connection with the Merger.

F2 · derivative.exercise_date: These options are fully vested and exercisable.

F4 · ownership.nature: These shares are jointly held by the reporting person and Jennifer Rivard as trustees for the Paul Rivard and Jennifer Rivard Revocable Living Trust.

SEC source: 0001493152-21-009302 · ownership.xml · derivative · entry 1

Rivard Paul · CIK 0001857479 · EVP of Operations, GC

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 77,180

Underlying: Common Stock · 77,180 shares

Expires 2023-04-16

F1 · price: Received in exchange for a stock option to acquire 200,000 shares of common stock of a private company formerly known as "MyMD Pharmaceuticals, Inc." (the "Former Entity") at $1.00 per share in connection with the merger of the Former Entity with and into a wholly owned subsidiary of the Issuer (the "Merger"). On the effective date of the Merger, the closing price of the Issuer's common stock was $4.94 per share.

F2 · derivative.exercise_date: These options are fully vested and exercisable.

SEC source: 0001493152-21-009294 · ownership.xml · derivative · entry 3

Silverman Joshua · CIK 0001524858 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 109,500 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of common stock of MyMD Pharmaceuticals, Inc. (the "Company").

F3 · derivative.exercise_date: On September 11, 2020, the reporting person was granted 109,500 RSUs of the Company, which vested on April 16, 2021, upon the occurrence of a change in control.

F3 · derivative.expiration_date: On September 11, 2020, the reporting person was granted 109,500 RSUs of the Company, which vested on April 16, 2021, upon the occurrence of a change in control.

SEC source: 0001493152-21-009294 · ownership.xml · nonDerivative · entry 2

Silverman Joshua · CIK 0001524858 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 71,175

F2 · shares: Represents 38,325 shares of RSUs withheld to pay the reporting person's tax withholding obligations incurred in connection with the vesting of 109,500 shares of RSUs on April 16, 2021.

SEC source: 0001493152-21-009294 · ownership.xml · nonDerivative · entry 1

Silverman Joshua · CIK 0001524858 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 112,101

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · shares: Each restricted stock unit ("RSU") represents a contingent right to receive one share of common stock of MyMD Pharmaceuticals, Inc. (the "Company").

F1 · price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of common stock of MyMD Pharmaceuticals, Inc. (the "Company").

SEC source: 0001493152-21-009409 · ownership.xml · derivative · entry 1

Kaplin Adam · CIK 0001858042 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 154,360

Underlying: Common Stock · 154,360 shares

Expires 2023-04-16

F1 · price: Received in exchange for a stock option to acquire 400,000 shares of common stock of a private company formerly known as "MyMD Pharmaceuticals, Inc." (the "Former Entity") at $1.00 per share in connection with the merger of the Former Entity with and into a wholly owned subsidiary of the Issuer (the "Merger"). On the effective date of the Merger, the closing price of the Issuer's common stock was $4.94 per share.

F2 · derivative.exercise_date: These options are fully vested and exercisable.

SEC source: 0001493152-21-009398 · ownership.xml · derivative · entry 3

Schreiber Christopher C · CIK 0001750076 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 131,750 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of common stock of MyMD Pharmaceuticals, Inc. (the "Company").

F3 · derivative.exercise_date: On September 11, 2020, the reporting person was granted 131,750 RSUs of the Company, which vested on April 16, 2021, upon the occurrence of a change in control.

F3 · derivative.expiration_date: On September 11, 2020, the reporting person was granted 131,750 RSUs of the Company, which vested on April 16, 2021, upon the occurrence of a change in control.

SEC source: 0001493152-21-009398 · ownership.xml · nonDerivative · entry 2

Schreiber Christopher C · CIK 0001750076 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 88,238

F2 · shares: Represents 46,113 shares of RSUs withheld to pay the reporting person's tax withholding obligations incurred in connection with the vesting of 131,750 shares of RSUs on April 16, 2021.

SEC source: 0001493152-21-009398 · ownership.xml · nonDerivative · entry 1

Schreiber Christopher C · CIK 0001750076 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 134,351

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · shares: Each restricted stock unit ("RSU") represents a contingent right to receive one share of common stock of MyMD Pharmaceuticals, Inc. (the "Company").

F1 · price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of common stock of MyMD Pharmaceuticals, Inc. (the "Company").

SEC source: 0001493152-21-009387 · ownership.xml · derivative · entry 1

Uzonwanne Jude · CIK 0001858040 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 115,770

Underlying: Common Stock · 115,770 shares

Expires 2023-04-16

F1 · price: Received in exchange for a stock option to acquire 300,000 shares of common stock of a private company formerly known as "MyMD Pharmaceuticals, Inc." (the "Former Entity") at $1.00 per share in connection with the merger of the Former Entity with and into a wholly owned subsidiary of the Issuer (the "Merger"). On the effective date of the Merger, the closing price of the Issuer's common stock was $4.94 per share.

F2 · derivative.exercise_date: The shares underlying this stock option shall vest according to the following schedule: 50% on October 26, 2021 and 50% on October 26, 2022.

SEC source: 0001493152-21-009385 · ownership.xml · derivative · entry 5

Chapman Christopher C JR · CIK 0001340428 · Director · President, Chief Med. Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 96,475

Underlying: Common Stock · 96,475 shares

Expires 2023-04-16

F6 · price: Received in the Merger in exchange for a stock option to acquire 250,000 shares of common stock of the Former Entity at $1.00 per share.

F3 · derivative.exercise_date: These options are fully vested and exercisable.

SEC source: 0001493152-21-009385 · ownership.xml · derivative · entry 4

Chapman Christopher C JR · CIK 0001340428 · Director · President, Chief Med. Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 77,180

Underlying: Common Stock · 77,180 shares

Expires 2023-04-16

F5 · price: Received in the Merger in exchange for a stock option to acquire 200,000 shares of common stock of the Former Entity at $1.00 per share.

F3 · derivative.exercise_date: These options are fully vested and exercisable.

SEC source: 0001493152-21-009385 · ownership.xml · derivative · entry 3

Chapman Christopher C JR · CIK 0001340428 · Director · President, Chief Med. Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 77,180

Underlying: Common Stock · 77,180 shares

Expires 2023-04-16

F4 · price: Received in the Merger in exchange for a stock option to acquire 200,000 shares of common stock of the Former Entity at $1.00 per share.

F3 · derivative.exercise_date: These options are fully vested and exercisable.

SEC source: 0001493152-21-009385 · ownership.xml · derivative · entry 2

Chapman Christopher C JR · CIK 0001340428 · Director · President, Chief Med. Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 38,590

Underlying: Common Stock · 38,590 shares

Expires 2023-04-16

F2 · price: Received in the Merger in exchange for a stock option to acquire 100,000 shares of common stock of the Former Entity at $1.00 per share.

F3 · derivative.exercise_date: These options are fully vested and exercisable.

SEC source: 0001493152-21-009385 · ownership.xml · nonDerivative · entry 1

Chapman Christopher C JR · CIK 0001340428 · Director · President, Chief Med. Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 96,475

F1 · price: Received in exchange for 250,000 shares of common stock of a private company formerly known as "MyMD Pharmaceuticals, Inc." (the "Former Entity") in connection with the merger of the Former Entity with and into a wholly owned subsidiary of the Issuer (the "Merger"). On the effective date of the Merger, the closing price of the Issuer's common stock was $4.94 per share.

SEC source: 0001493152-21-009498 · ownership.xml · derivative · entry 1

EAGLE CRAIG · CIK 0001562135 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 482,375

Underlying: Common Stock · 482,375 shares

Expires 2023-04-16

F1 · price: Received in exchange for a stock option to acquire 1,250,000 shares of common stock of a private company formerly known as "MyMD Pharmaceuticals, Inc." (the "Former Entity") at $1.00 per share in connection with the merger of the Former Entity with and into a wholly owned subsidiary of the Issuer (the "Merger"). On the effective date of the Merger, the closing price of the Issuer's common stock was $4.94 per share.

F2 · derivative.exercise_date: These options are fully vested and exercisable.

SEC source: 0001493152-20-017674 · ownership.xml · derivative · entry 1

White Billy Joe · CIK 0001546805 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 219,000

Underlying: Common Stock · 219,000 shares

Expires not disclosed

F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of common stock of Akers Biosciences, Inc. (the "Company"). The Company may also elect to settle the vested RSUs for cash at its discretion.

F2 · derivative.exercise_date: Reporting Person was granted 219,000 RSUs under the Company's 2018 Equity Incentive Plan, as amended (the "Plan"), with fifty percent (50%) of the RSUs to vest on the first anniversary of the date of grant, and the remaining fifty percent (50%) to vest on the second anniversary of the date of grant; provided that the RSUs shall vest immediately upon the occurrence of (i) a change in control, provided that the Reporting Person is employed by or providing services to the Company and its affiliates on the closing date of such change in control, (ii) the Reporting Person's termination of employment or service from the Company and its affiliates by reason of the Reporting Person's death or disability, or (iii) the Reporting Person's termination of employment or service by the Company without cause.

F2 · derivative.expiration_date: Reporting Person was granted 219,000 RSUs under the Company's 2018 Equity Incentive Plan, as amended (the "Plan"), with fifty percent (50%) of the RSUs to vest on the first anniversary of the date of grant, and the remaining fifty percent (50%) to vest on the second anniversary of the date of grant; provided that the RSUs shall vest immediately upon the occurrence of (i) a change in control, provided that the Reporting Person is employed by or providing services to the Company and its affiliates on the closing date of such change in control, (ii) the Reporting Person's termination of employment or service from the Company and its affiliates by reason of the Reporting Person's death or disability, or (iii) the Reporting Person's termination of employment or service by the Company without cause.

SEC source: 0001493152-20-017670 · ownership.xml · derivative · entry 1

SCHROEDER ROBERT C · CIK 0001268331 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 87,860

Underlying: Common Stock · 87,860 shares

Expires not disclosed

F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of common stock of Akers Biosciences, Inc. (the "Company"). The Company may also elect to settle the vested RSUs for cash at its discretion.

F2 · derivative.exercise_date: Reporting Person was granted 87,860 RSUs under the Company's 2018 Equity Incentive Plan, as amended (the "Plan"), with fifty percent (50%) of the RSUs to vest on the first anniversary of the date of grant, and the remaining fifty percent (50%) to vest on the second anniversary of the date of grant; provided that the RSUs shall vest immediately upon the occurrence of (i) a change in control, provided that the Reporting Person is employed by or providing services to the Company and its affiliates on the closing date of such change in control, (ii) the Reporting Person's termination of employment or service from the Company and its affiliates by reason of the Reporting Person's death or disability, or (iii) the Reporting Person's termination of employment or service by the Company without cause.

F2 · derivative.expiration_date: Reporting Person was granted 87,860 RSUs under the Company's 2018 Equity Incentive Plan, as amended (the "Plan"), with fifty percent (50%) of the RSUs to vest on the first anniversary of the date of grant, and the remaining fifty percent (50%) to vest on the second anniversary of the date of grant; provided that the RSUs shall vest immediately upon the occurrence of (i) a change in control, provided that the Reporting Person is employed by or providing services to the Company and its affiliates on the closing date of such change in control, (ii) the Reporting Person's termination of employment or service from the Company and its affiliates by reason of the Reporting Person's death or disability, or (iii) the Reporting Person's termination of employment or service by the Company without cause.

SEC source: 0001493152-20-017672 · ownership.xml · derivative · entry 1

Silverman Joshua · CIK 0001524858 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 219,000

Underlying: Common Stock · 219,000 shares

Expires not disclosed

F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of common stock of Akers Biosciences, Inc. (the "Company"). The Company may also elect to settle the vested RSUs for cash at its discretion.

F2 · derivative.exercise_date: Reporting Person was granted 219,000 RSUs under the Company's 2018 Equity Incentive Plan, as amended (the "Plan"), with fifty percent (50%) of the RSUs to vest on the first anniversary of the date of grant, and the remaining fifty percent (50%) to vest on the second anniversary of the date of grant; provided that the RSUs shall vest immediately upon the occurrence of (i) a change in control, provided that the Reporting Person is employed by or providing services to the Company and its affiliates on the closing date of such change in control, (ii) the Reporting Person's termination of employment or service from the Company and its affiliates by reason of the Reporting Person's death or disability, or (iii) the Reporting Person's termination of employment or service by the Company without cause.

F2 · derivative.expiration_date: Reporting Person was granted 219,000 RSUs under the Company's 2018 Equity Incentive Plan, as amended (the "Plan"), with fifty percent (50%) of the RSUs to vest on the first anniversary of the date of grant, and the remaining fifty percent (50%) to vest on the second anniversary of the date of grant; provided that the RSUs shall vest immediately upon the occurrence of (i) a change in control, provided that the Reporting Person is employed by or providing services to the Company and its affiliates on the closing date of such change in control, (ii) the Reporting Person's termination of employment or service from the Company and its affiliates by reason of the Reporting Person's death or disability, or (iii) the Reporting Person's termination of employment or service by the Company without cause.

SEC source: 0001493152-20-017668 · ownership.xml · derivative · entry 1

Schreiber Christopher C · CIK 0001750076 · Director · Exec. Chairman and President

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 263,500

Underlying: Common Stock · 263,500 shares

Expires not disclosed

F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of common stock of Akers Biosciences, Inc. (the "Company"). The Company may also elect to settle the vested RSUs for cash at its discretion.

F2 · derivative.exercise_date: Reporting Person was granted 263,500 RSUs under the Company's 2018 Equity Incentive Plan, as amended (the "Plan"), with fifty percent (50%) of the RSUs to vest on the first anniversary of the date of grant, and the remaining fifty percent (50%) to vest on the second anniversary of the date of grant; provided that the RSUs shall vest immediately upon the occurrence of (i) a change in control, provided that the Reporting Person is employed by or providing services to the Company and its affiliates on the closing date of such change in control, (ii) the Reporting Person's termination of employment or service from the Company and its affiliates by reason of the Reporting Person's death or disability, or (iii) the Reporting Person's termination of employment or service by the Company without cause.

F2 · derivative.expiration_date: Reporting Person was granted 263,500 RSUs under the Company's 2018 Equity Incentive Plan, as amended (the "Plan"), with fifty percent (50%) of the RSUs to vest on the first anniversary of the date of grant, and the remaining fifty percent (50%) to vest on the second anniversary of the date of grant; provided that the RSUs shall vest immediately upon the occurrence of (i) a change in control, provided that the Reporting Person is employed by or providing services to the Company and its affiliates on the closing date of such change in control, (ii) the Reporting Person's termination of employment or service from the Company and its affiliates by reason of the Reporting Person's death or disability, or (iii) the Reporting Person's termination of employment or service by the Company without cause.

SEC source: 0001393825-20-000097 · primary_doc.xml · nonDerivative · entry 1

Hudson Bay Capital Management LP · CIK 0001393825 · 10% owner

Gerber Sander · CIK 0001416593 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 240,305

F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.82 to $2.83, inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein.

F2 · ownership.nature: The securities are held by Hudson Bay Master Fund, Ltd. (the "Fund"). Hudson Bay Capital Management LP (the "Investment Manager") serves as the investment manager of the Fund. As such, the Investment Manager may be deemed to have beneficial ownership of the securities held by the Fund. As the managing member of the general partner of Hudson Bay Capital Management LP, Mr. Sander Gerber may be deemed to have beneficial ownership of the securities held by the Fund. Each Reporting Person disclaims beneficial ownership of the securities held by the Fund, except to the extent of its or his pecuniary interest therein.

SEC source: 0001393825-20-000096 · primary_doc.xml · nonDerivative · entry 2

Hudson Bay Capital Management LP · CIK 0001393825 · 10% owner

Gerber Sander · CIK 0001416593 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 240,943

F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.72 to $2.80, inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein.

F2 · ownership.nature: The securities are held by Hudson Bay Master Fund, Ltd. (the "Fund"). Hudson Bay Capital Management LP (the "Investment Manager") serves as the investment manager of the Fund. As such, the Investment Manager may be deemed to have beneficial ownership of the securities held by the Fund. As the managing member of the general partner of Hudson Bay Capital Management LP, Mr. Sander Gerber may be deemed to have beneficial ownership of the securities held by the Fund. Each Reporting Person disclaims beneficial ownership of the securities held by the Fund, except to the extent of its or his pecuniary interest therein.

SEC source: 0001393825-20-000096 · primary_doc.xml · nonDerivative · entry 1

Hudson Bay Capital Management LP · CIK 0001393825 · 10% owner

Gerber Sander · CIK 0001416593 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 256,243

F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.87 to $2.93, inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein.

F2 · ownership.nature: The securities are held by Hudson Bay Master Fund, Ltd. (the "Fund"). Hudson Bay Capital Management LP (the "Investment Manager") serves as the investment manager of the Fund. As such, the Investment Manager may be deemed to have beneficial ownership of the securities held by the Fund. As the managing member of the general partner of Hudson Bay Capital Management LP, Mr. Sander Gerber may be deemed to have beneficial ownership of the securities held by the Fund. Each Reporting Person disclaims beneficial ownership of the securities held by the Fund, except to the extent of its or his pecuniary interest therein.

SEC source: 0001493152-20-000165 · ownership.xml · derivative · entry 2

White Billy Joe · CIK 0001546805 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 5,201 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of common stock of Akers Biosciences, Inc. (the "Company").

F2 · derivative.exercise_date: On March 29, 2019, the reporting person was granted 5,201 RSUs of the Company, which vested on January 1, 2020.

F2 · derivative.expiration_date: On March 29, 2019, the reporting person was granted 5,201 RSUs of the Company, which vested on January 1, 2020.

SEC source: 0001493152-20-000165 · ownership.xml · nonDerivative · entry 1

White Billy Joe · CIK 0001546805 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 5,201

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of common stock of Akers Biosciences, Inc. (the "Company").

SEC source: 0001493152-20-000166 · ownership.xml · derivative · entry 2

Schreiber Christopher C · CIK 0001750076 · Director · Executive Chairman

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 5,201 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of common stock of Akers Biosciences, Inc. (the "Company").

F2 · derivative.exercise_date: On March 29, 2019, the reporting person was granted 5,201 RSUs of the Company, which vested on January 1, 2020.

F2 · derivative.expiration_date: On March 29, 2019, the reporting person was granted 5,201 RSUs of the Company, which vested on January 1, 2020.

SEC source: 0001493152-20-000166 · ownership.xml · nonDerivative · entry 1

Schreiber Christopher C · CIK 0001750076 · Director · Executive Chairman

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 5,201

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of common stock of Akers Biosciences, Inc. (the "Company").

SEC source: 0001493152-20-000164 · ownership.xml · derivative · entry 2

Silverman Joshua · CIK 0001524858 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 5,201 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of common stock of Akers Biosciences, Inc. (the "Company").

F2 · derivative.exercise_date: On March 29, 2019, the reporting person was granted 5,201 RSUs of the Company, which vested on January 1, 2020.

F2 · derivative.expiration_date: On March 29, 2019, the reporting person was granted 5,201 RSUs of the Company, which vested on January 1, 2020.

SEC source: 0001493152-20-000164 · ownership.xml · nonDerivative · entry 1

Silverman Joshua · CIK 0001524858 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 5,201

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of common stock of Akers Biosciences, Inc. (the "Company").

SEC source: 0001393825-20-000002 · primary_doc.xml · nonDerivative · entry 12

Hudson Bay Capital Management LP · CIK 0001393825 · 10% owner

Gerber Sander · CIK 0001416593 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 269,243

F1 · ownership.nature: The securities are held by Hudson Bay Master Fund, Ltd. (the "Fund"). Hudson Bay Capital Management LP (the "Investment Manager") serves as the investment manager of the Fund. As such, the Investment Manager may be deemed to have beneficial ownership of the securities held by the Fund. As the managing member of the general partner of Hudson Bay Capital Management LP, Mr. Sander Gerber may be deemed to have beneficial ownership of the securities held by the Fund. Each Reporting Person disclaims beneficial ownership of the securities held by the Fund, except to the extent of its or his pecuniary interest therein.

SEC source: 0001393825-20-000002 · primary_doc.xml · nonDerivative · entry 11

Hudson Bay Capital Management LP · CIK 0001393825 · 10% owner

Gerber Sander · CIK 0001416593 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 261,243

F1 · ownership.nature: The securities are held by Hudson Bay Master Fund, Ltd. (the "Fund"). Hudson Bay Capital Management LP (the "Investment Manager") serves as the investment manager of the Fund. As such, the Investment Manager may be deemed to have beneficial ownership of the securities held by the Fund. As the managing member of the general partner of Hudson Bay Capital Management LP, Mr. Sander Gerber may be deemed to have beneficial ownership of the securities held by the Fund. Each Reporting Person disclaims beneficial ownership of the securities held by the Fund, except to the extent of its or his pecuniary interest therein.

SEC source: 0001393825-20-000002 · primary_doc.xml · nonDerivative · entry 10

Hudson Bay Capital Management LP · CIK 0001393825 · 10% owner

Gerber Sander · CIK 0001416593 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 258,043

F1 · ownership.nature: The securities are held by Hudson Bay Master Fund, Ltd. (the "Fund"). Hudson Bay Capital Management LP (the "Investment Manager") serves as the investment manager of the Fund. As such, the Investment Manager may be deemed to have beneficial ownership of the securities held by the Fund. As the managing member of the general partner of Hudson Bay Capital Management LP, Mr. Sander Gerber may be deemed to have beneficial ownership of the securities held by the Fund. Each Reporting Person disclaims beneficial ownership of the securities held by the Fund, except to the extent of its or his pecuniary interest therein.

SEC source: 0001393825-20-000002 · primary_doc.xml · nonDerivative · entry 9

Hudson Bay Capital Management LP · CIK 0001393825 · 10% owner

Gerber Sander · CIK 0001416593 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 251,043

F1 · ownership.nature: The securities are held by Hudson Bay Master Fund, Ltd. (the "Fund"). Hudson Bay Capital Management LP (the "Investment Manager") serves as the investment manager of the Fund. As such, the Investment Manager may be deemed to have beneficial ownership of the securities held by the Fund. As the managing member of the general partner of Hudson Bay Capital Management LP, Mr. Sander Gerber may be deemed to have beneficial ownership of the securities held by the Fund. Each Reporting Person disclaims beneficial ownership of the securities held by the Fund, except to the extent of its or his pecuniary interest therein.

SEC source: 0001393825-20-000002 · primary_doc.xml · nonDerivative · entry 8

Hudson Bay Capital Management LP · CIK 0001393825 · 10% owner

Gerber Sander · CIK 0001416593 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 248,043

F1 · ownership.nature: The securities are held by Hudson Bay Master Fund, Ltd. (the "Fund"). Hudson Bay Capital Management LP (the "Investment Manager") serves as the investment manager of the Fund. As such, the Investment Manager may be deemed to have beneficial ownership of the securities held by the Fund. As the managing member of the general partner of Hudson Bay Capital Management LP, Mr. Sander Gerber may be deemed to have beneficial ownership of the securities held by the Fund. Each Reporting Person disclaims beneficial ownership of the securities held by the Fund, except to the extent of its or his pecuniary interest therein.

SEC source: 0001393825-20-000002 · primary_doc.xml · nonDerivative · entry 7

Hudson Bay Capital Management LP · CIK 0001393825 · 10% owner

Gerber Sander · CIK 0001416593 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 243,043

F1 · ownership.nature: The securities are held by Hudson Bay Master Fund, Ltd. (the "Fund"). Hudson Bay Capital Management LP (the "Investment Manager") serves as the investment manager of the Fund. As such, the Investment Manager may be deemed to have beneficial ownership of the securities held by the Fund. As the managing member of the general partner of Hudson Bay Capital Management LP, Mr. Sander Gerber may be deemed to have beneficial ownership of the securities held by the Fund. Each Reporting Person disclaims beneficial ownership of the securities held by the Fund, except to the extent of its or his pecuniary interest therein.

SEC source: 0001393825-20-000002 · primary_doc.xml · nonDerivative · entry 6

Hudson Bay Capital Management LP · CIK 0001393825 · 10% owner

Gerber Sander · CIK 0001416593 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 237,043

F1 · ownership.nature: The securities are held by Hudson Bay Master Fund, Ltd. (the "Fund"). Hudson Bay Capital Management LP (the "Investment Manager") serves as the investment manager of the Fund. As such, the Investment Manager may be deemed to have beneficial ownership of the securities held by the Fund. As the managing member of the general partner of Hudson Bay Capital Management LP, Mr. Sander Gerber may be deemed to have beneficial ownership of the securities held by the Fund. Each Reporting Person disclaims beneficial ownership of the securities held by the Fund, except to the extent of its or his pecuniary interest therein.

SEC source: 0001393825-20-000002 · primary_doc.xml · nonDerivative · entry 5

Hudson Bay Capital Management LP · CIK 0001393825 · 10% owner

Gerber Sander · CIK 0001416593 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 216,443

F1 · ownership.nature: The securities are held by Hudson Bay Master Fund, Ltd. (the "Fund"). Hudson Bay Capital Management LP (the "Investment Manager") serves as the investment manager of the Fund. As such, the Investment Manager may be deemed to have beneficial ownership of the securities held by the Fund. As the managing member of the general partner of Hudson Bay Capital Management LP, Mr. Sander Gerber may be deemed to have beneficial ownership of the securities held by the Fund. Each Reporting Person disclaims beneficial ownership of the securities held by the Fund, except to the extent of its or his pecuniary interest therein.

SEC source: 0001393825-20-000002 · primary_doc.xml · nonDerivative · entry 4

Hudson Bay Capital Management LP · CIK 0001393825 · 10% owner

Gerber Sander · CIK 0001416593 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 210,424

F1 · ownership.nature: The securities are held by Hudson Bay Master Fund, Ltd. (the "Fund"). Hudson Bay Capital Management LP (the "Investment Manager") serves as the investment manager of the Fund. As such, the Investment Manager may be deemed to have beneficial ownership of the securities held by the Fund. As the managing member of the general partner of Hudson Bay Capital Management LP, Mr. Sander Gerber may be deemed to have beneficial ownership of the securities held by the Fund. Each Reporting Person disclaims beneficial ownership of the securities held by the Fund, except to the extent of its or his pecuniary interest therein.

SEC source: 0001393825-20-000002 · primary_doc.xml · nonDerivative · entry 3

Hudson Bay Capital Management LP · CIK 0001393825 · 10% owner

Gerber Sander · CIK 0001416593 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 184,018

F1 · ownership.nature: The securities are held by Hudson Bay Master Fund, Ltd. (the "Fund"). Hudson Bay Capital Management LP (the "Investment Manager") serves as the investment manager of the Fund. As such, the Investment Manager may be deemed to have beneficial ownership of the securities held by the Fund. As the managing member of the general partner of Hudson Bay Capital Management LP, Mr. Sander Gerber may be deemed to have beneficial ownership of the securities held by the Fund. Each Reporting Person disclaims beneficial ownership of the securities held by the Fund, except to the extent of its or his pecuniary interest therein.